Monday, September 21, 2020

Avacta expands manufacturing capacity for rapid COVID antigen test

Avacta Group, the Wetherby-based life science business, has expanded its rapid COVID-19 antigen test manufacturing capacity.

The AIM listed firm has entered into an agreement with Abingdon Health – whose two sites are based in York and Doncaster – for the manufacture of its saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expansion of manufacturing capacity.

Working in partnership with Cytiva, Avacta is developing a rapid test strip for use with patient saliva that aims to provide a result in a few minutes, indicating whether the patient is currently infected with the SARS-CoV-2 coronavirus.

The test has the potential to be used for frequent mass testing of the population to promptly identify infectious individuals so that they can be isolated and treated, thereby reducing the spread of infection.

The company recently announced a manufacturing partnership with BBI Solutions to develop and validate a scaled-up manufacturing process for the rapid coronavirus antigen test.

Avacta, Cytiva and BBI are in the process of technology transfer of the prototype and related manufacturing procedures for the test. Avacta aims to begin clinical validation of the test as soon as possible using the first pilot batches.

Technology transfer to Abingdon Health will begin immediately with the aim of manufacturing an equivalent rapid antigen test product which therefore does not require additional clinical validation/regulatory approvals.

The agreement with Abingdon Health will provide additional manufacturing capacity that could increase to several millions of tests per month.

“The Affimer reagents that we have generated are very specific to SARS-CoV-2 antigen and we are confident of meeting and exceeding the clinical performance requirements for identifying the most infectious people,” said Dr Alastair Smith, Chief Executive of Avacta Group.

“Manufacturing capacity is therefore the key challenge that has to be met in achieving widespread roll-out of Avacta’s saliva-based rapid antigen test.

“We therefore continue to actively seek additional manufacturing partners globally to be able to provide the volume of tests that will be required in the UK and elsewhere.”

Chris Yates, CEO of Abingdon Health, added:  “We are pleased to be working with Avacta on this saliva-based COVID-19 test. Abingdon Health is working at the forefront of COVID-19 rapid testing and we are delighted to expand our reach further to support deployment of mass testing to help in the fight to combat the COVID-19 global pandemic.

“We have invested in our manufacturing capacity over the past few months and stand ready to support deployment of high volume, quality, rapid lateral flow tests.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site and magazine but journalism costs money and we rely on advertising, print and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites/magazines with either a small donation of even £1, or a subscription to our magazine, which costs just £31.50 per year, (inc p&P and mailed direct to your door) your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

As a subscriber, you will have unlimited access to our web site and magazine. You'll also be offered VIP invitations to our events, preferential rates to all our awards and get access to exclusive newsletters and content.

Just click here to subscribe and in the meantime may I wish you the very best.




Latest news

York hotel plan gets go-ahead

A new hotel is to be built on Micklegate in York, after planning approval was granted by just one vote. The 62 bedroom hotel, with...

Hull’s Whitefriargate secures £1.75m grant from Historic England

Whitefriargate in Hull has received a grant of £1.75m from Historic England. Hull City Council was informed earlier this year that its funding bid, for...

Facelift planned for prominent Sheffield building

A planning application proposing a significant facelift to Sheffield's Gaumont building, located on the junction between Barker’s Pool and Burgess Street in the city...

Pandemic sees major slide in recruitment plans as firms play it safe

Almost half of firms in the UK plan to reduce recruitment or not recruit at all over the next year, according to an annual...

The times they are a-changing

Bob Dylan’s immortal words couldn’t be more accurate in this day and age as many of us are having to learn new skills and...

NPIF cash for Sheffield smart sensor company

Sheffield tech company, Tribosonics, has raised £1.1 million to develop and grow its smart sensors which helps industry reduce costs. The company embeds sensors within...

Related news

York hotel plan gets go-ahead

A new hotel is to be built on Micklegate in York, after planning approval was granted by just one vote. The 62 bedroom hotel, with...

Hull’s Whitefriargate secures £1.75m grant from Historic England

Whitefriargate in Hull has received a grant of £1.75m from Historic England. Hull City Council was informed earlier this year that its funding bid, for...

Facelift planned for prominent Sheffield building

A planning application proposing a significant facelift to Sheffield's Gaumont building, located on the junction between Barker’s Pool and Burgess Street in the city...

Pandemic sees major slide in recruitment plans as firms play it safe

Almost half of firms in the UK plan to reduce recruitment or not recruit at all over the next year, according to an annual...

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close